Cynata Therapeutics Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYYNF research report →
Companywww.cynata.com
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.
- CEO
- Kilian Kelly
- IPO
- 2015
- Employees
- 2
- HQ
- Cremorne, VIC, AU
Price Chart
Valuation
- Market Cap
- $54.07M
- P/E
- -8.06
- P/S
- -830.75
- P/B
- 19.99
- EV/EBITDA
- -6.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 253.27%
- Op Margin
- 16974.06%
- Net Margin
- 9887.90%
- ROE
- -179.37%
- ROIC
- -353.74%
Growth & Income
- Revenue
- $1.89M · -18.59%
- Net Income
- $-9,390,586 · 3.63%
- EPS
- $-0.05 · 15.50%
- Op Income
- $-8,124,003
- FCF YoY
- 11.95%
Performance & Tape
- 52W High
- $0.22
- 52W Low
- $0.08
- 50D MA
- $0.22
- 200D MA
- $0.17
- Beta
- 1.08
- Avg Volume
- 6
Get TickerSpark's AI analysis on CYYNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CYYNF Coverage
We haven't published any research on CYYNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CYYNF Report →